Anti-BCAP/ PIK3AP1 monoclonal antibody

Anti-BCAP/ PIK3AP1 antibody for FACS & in-vivo assay

Target products collectionGo to PIK3AP1/PIK3AP1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2241-Ab-1/ GM-Tg-hg-MP2241-Ab-2Anti-Human PIK3AP1 monoclonal antibodyHuman
GM-Tg-rg-MP2241-Ab-1/ GM-Tg-rg-MP2241-Ab-2Anti-Rat PIK3AP1 monoclonal antibodyRat
GM-Tg-mg-MP2241-Ab-1/ GM-Tg-mg-MP2241-Ab-2Anti-Mouse PIK3AP1 monoclonal antibodyMouse
GM-Tg-cynog-MP2241-Ab-1/ GM-Tg-cynog-MP2241-Ab-2Anti-Cynomolgus/ Rhesus macaque PIK3AP1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2241-Ab-1/ GM-Tg-felg-MP2241-Ab-2Anti-Feline PIK3AP1 monoclonal antibodyFeline
GM-Tg-cang-MP2241-Ab-1/ GM-Tg-cang-MP2241-Ab-2Anti-Canine PIK3AP1 monoclonal antibodyCanine
GM-Tg-bovg-MP2241-Ab-1/ GM-Tg-bovg-MP2241-Ab-2Anti-Bovine PIK3AP1 monoclonal antibodyBovine
GM-Tg-equg-MP2241-Ab-1/ GM-Tg-equg-MP2241-Ab-2Anti-Equine PIK3AP1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2241-Ab-1/ GM-Tg-hg-MP2241-Ab-2; GM-Tg-rg-MP2241-Ab-1/ GM-Tg-rg-MP2241-Ab-2;
GM-Tg-mg-MP2241-Ab-1/ GM-Tg-mg-MP2241-Ab-2; GM-Tg-cynog-MP2241-Ab-1/ GM-Tg-cynog-MP2241-Ab-2;
GM-Tg-felg-MP2241-Ab-1/ GM-Tg-felg-MP2241-Ab-2; GM-Tg-cang-MP2241-Ab-1/ GM-Tg-cang-MP2241-Ab-2;
GM-Tg-bovg-MP2241-Ab-1/ GM-Tg-bovg-MP2241-Ab-2; GM-Tg-equg-MP2241-Ab-1/ GM-Tg-equg-MP2241-Ab-2
Products NameAnti-PIK3AP1 monoclonal antibody
Formatmab
Target NamePIK3AP1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PIK3AP1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species BCAP/ PIK3AP1 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2241
    Target NamePIK3AP1
    Gene ID118788,83490,294048,705017,608653,101086927,100138311,100070796
    Gene Symbol and Synonyms1810044J04Rik,BCAP,PIK3AP1
    Uniprot AccessionQ6ZUJ8
    Uniprot Entry NameBCAP_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000155629
    Target ClassificationN/A

    The target: PIK3AP1, gene name: PIK3AP1, also named as BCAP. Predicted to enable phosphatidylinositol 3-kinase regulatory subunit binding activity and signaling receptor binding activity. Predicted to be involved in regulation of inflammatory response; regulation of signal transduction; and toll-like receptor signaling pathway. Predicted to be located in cytoplasm and membrane. Predicted to be active in cytosol. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.